Metabolism-Related Genes SMOX and SUCLG2 as Immunological and Prognostic Biomarkers in Colorectal Cancer: A Pan-Cancer Analysis.

Expression patterns and underlying mechanisms of metabolism-related genes SMOX and SUCLG2 in pan-cancer remain unclear. We conducted a comprehensive pan-cancer analysis of SMOX and SUCLG2, to explore their potential roles and mechanisms of action. Comprehensive analysis of SMOX and SUCLG2 was performed through UCSC, TCGA, GEO, and other databases. We validated the expression levels, diagnostic value, and prognostic significance of SMOX and SUCLG2 in CRC using external databases and qPCR. Then, CCK-8 is used to detect proliferation of RKO and HCT116 after silencing or overexpressing of SUCLG2. The expression of SMOX was upregulated and that of SUCLG2 was downregulated in most cancers. Both SMOX and SUCLG2 exhibited significant correlations with cancer prognosis, tumor microenvironment, immune infiltration, stemness scores, tumor mutational burden, and microsatellite instability. The diagnostic and prognostic value of SMOX and SUCLG2 in CRC was confirmed through TCGA, GEO, and HPA, as well as qPCR. SUCLG2 overexpression inhibited the proliferation of RKO and HCT116, whereas SUCLG2 silence promoted their proliferation. Our data provide insights into the role of SMOX and SUCLG2 in pan-cancer, highlighting their association with prognosis, cancer immunity, and other cancer characteristics and also revealing their significance in cancer progression. SUCLG2 may inhibit the proliferation of CRC.